Transferrin in normal and neoplastic endocervical tissues: distribution and receptor expression. 1998

J Farley, and D Loup, and M Nelson, and M J Miller, and R Taylor, and K Gray
Department of Obstetrics and Gynecology, Uniformed Services University of Health Sciences, Bethesda, USA.

OBJECTIVE Our recent studies showed that lactoferrin seems to be down-regulated in endocervical adenocarcinomas. We extended those studies to examine the expression of transferrin (Tf) and its receptor (TfR) in endocervical carcinogenesis and any relationship to the expression of lactoferrin, steroid receptors and the proliferative index. METHODS A retrospective study was performed using sections prepared from paraffin-embedded, formalin-fixed surgical specimens of normal endocervix, endocervical adenocarcinoma and cervical adenocarcinoma in situ. Standard immunohistochemical techniques were used to localize Tf and its receptor in the normal and malignant endocervix. In situ detection of mRNA for Tf and the TfR was also performed. The relative intensity of the immunoreaction was estimated using digital computer image analysis. Statistical significance was tested by Student's t test. RESULTS No differences in the relative staining intensity for Tf and TfR proteins were noted between normal and neoplastic glands. However, quantitation revealed that a greater number of malignant glands stained positive for TfR than observed in the normal endocervix. Expression of Tf and TfR did not correlate with the expression of steroid receptors and lactoferrin or with the rate of proliferation. CONCLUSIONS We have demonstrated the expression of Tf and its receptor by both normal and malignant endocervical glands. The increased number of malignant endocervical glands expressing TfR may indicate a special requirement for Tf and the iron that it carries. Our data provide evidence for the existence of a Tf, TfR autocrine or paracrine circuit involved in the regulation of normal and abnormal endocervical physiology.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D011990 Receptors, Transferrin Membrane glycoproteins found in high concentrations on iron-utilizing cells. They specifically bind iron-bearing transferrin, are endocytosed with its ligand and then returned to the cell surface where transferrin without its iron is released. Transferrin Receptors,Transferrin Receptor,Receptor, Transferrin
D002278 Carcinoma in Situ A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane. Carcinoma, Intraepithelial,Carcinoma, Preinvasive,Intraepithelial Neoplasms,Neoplasms, Intraepithelial,Intraepithelial Carcinoma,Intraepithelial Neoplasm,Neoplasm, Intraepithelial,Preinvasive Carcinoma
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D002584 Cervix Uteri The neck portion of the UTERUS between the lower isthmus and the VAGINA forming the cervical canal. Cervical Canal of the Uterus,Cervical Canal, Uterine,Ectocervix,Endocervical Canal,Endocervix,External Os Cervix,External Os of the Cervix,Uterine Cervical Canal,Cervix,Cervixes,Uterine Cervix,Canal, Endocervical,Canal, Uterine Cervical,Cervix, External Os,Cervix, Uterine,Endocervical Canals,Uterine Cervical Canals
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective

Related Publications

J Farley, and D Loup, and M Nelson, and M J Miller, and R Taylor, and K Gray
November 2001, Blood,
J Farley, and D Loup, and M Nelson, and M J Miller, and R Taylor, and K Gray
February 2023, International journal of molecular sciences,
J Farley, and D Loup, and M Nelson, and M J Miller, and R Taylor, and K Gray
November 1991, Oncogene,
J Farley, and D Loup, and M Nelson, and M J Miller, and R Taylor, and K Gray
May 2024, Experimental and molecular pathology,
J Farley, and D Loup, and M Nelson, and M J Miller, and R Taylor, and K Gray
August 2004, Histopathology,
J Farley, and D Loup, and M Nelson, and M J Miller, and R Taylor, and K Gray
December 1986, Molecular and cellular biology,
J Farley, and D Loup, and M Nelson, and M J Miller, and R Taylor, and K Gray
July 1969, Archives of biochemistry and biophysics,
J Farley, and D Loup, and M Nelson, and M J Miller, and R Taylor, and K Gray
February 2004, Hybridoma and hybridomics,
J Farley, and D Loup, and M Nelson, and M J Miller, and R Taylor, and K Gray
April 2016, Pancreas,
J Farley, and D Loup, and M Nelson, and M J Miller, and R Taylor, and K Gray
November 2023, Scientific reports,
Copied contents to your clipboard!